Description :
Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation , mucus production , tighten of muscles . The general symptoms are coughing , wheezing , shortness of breath and / or chest tightness and majorly these symptoms are closely related to the physical activity . There are different types of asthma , exercise-induced bronchoconstriction ( EIB ), allergic asthma , occupational asthma , childhood asthma . Chronic Obstructive Pulmonary Disease ( COPD ) is also respiratory disease which causes obstructions and difficulty in breathing , the primary cause of COPD is tobacco smoking and chemical flumes , dust , air pollution are minor causes of the disease . Major symptoms are long lasting cough , mucus that comes out along with cough , shortness of breath .
Browse the full report @ http :// www . orbisresearch . com / reports / index / copd-andasthma-drugs-market-by-disease-medication-class-and-by-geography-global-opportunityanalysis-and-industry-forecasts-2014-2022 .
The world COPD and asthma drugs market is expected to reach $ 50,359 million by 2022 , growing at a CAGR of 3.7 % from 2016 to 2022 . Increase in prevalence of asthma and COPD , increase in world ageing population , technological advancement in the treatment of asthma and COPD , growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market . Stringent government regulatory requirement for the approval of COPD and asthma drug , patent expiry of branded hamper the market growth .
The world asthma and COPD drugs market is segmented based on disease and medication class and geography . On the basis of disease , the market is segmented into COPD and asthma . Based on medication class , the world asthma and COPD drug market is segmented into combination products , short acting beta agonists ( SABA ), long acting beta agonists ( LABA ), inhaled corticosteroids ( ICS ), leukotriene antagonists ( LTA ), anticholinergics and others . And geographically , the market is segmented into North America , Europe , Asia- Pacific , and LAMEA .
Check the DISCOUNT on this report @ http :// www . orbisresearch . com / contacts / discount / 220640 .
KEY PLAYERS GlaxoSmithKline ( GSK ) Novartis AG . Merck & Co . Abbott Laboratories . Boehringer Ingelheim . AstraZeneca . Roche Holding AG Teva Pharmaceutical Industries . Vectura Group Pfizer
2